Genetic Characteristics of EGFR Concurrent Variants with RB1 and TP53 in NCSLC Patients

被引：0
|
作者：
Chen, H. [1 ]
Yuan, S. [1 ]
Chen, L. [1 ]
Shi, X. [1 ]
Wang, L. [1 ]
Dong, X. [1 ]
Wang, M. [1 ]
Wang, A. [1 ]
Liu, W. [1 ]
Cui, Z. [1 ]
Chen, C. [1 ]
Mei, L. [1 ]
机构：
[1] Shanghai OrigiMed Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
EGFR-TKIs; NCSLC; EGFR/RB1/TP53;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP16.03-00
引用
下载
收藏
页码：S587 / S588
页数：2
相关论文
共 50 条
  • [1] Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers with Concurrent TP53 and RB1 Mutations
    Offin, M.
    Tenet, M.
    Shen, R.
    Rekhtman, N.
    Rizvi, H.
    Hellmann, M.
    Arcila, M.
    Ladanyi, M.
    Rudin, C.
    Kris, M.
    Yu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S412 - S412
  • [2] Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas
    Watanabe, T
    Yokoo, H
    Yokoo, M
    Yonekawa, Y
    Kleihues, P
    Ohgaki, H
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (12): : 1181 - 1189
  • [3] Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations
    Huang, J.
    Huang, W.
    Wang, Q.
    Zhang, C.
    Ni, S.
    Sun, D.
    Zhou, Y.
    Hou, T.
    Sun, W.
    Chen, Z.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S48 - S48
  • [4] Concurrent somatic alterations of TP53 and RB1 in Chinese lung adenocarcinoma with or without EGFR mutations.
    Wang, Jun
    Chen, Gang
    Zhang, Bicheng
    Sun, Jianguo
    Liang, Jing
    Liu, Xiaolin
    Li, Yan
    Wang, Baocheng
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] RB1 and TP53 pathways in radiation-induced sarcomas
    N Gonin-Laurent
    N S Hadj-Hamou
    N Vogt
    C Houdayer
    M Gauthiers-Villars
    C Dehainault
    X Sastre-Garau
    S Chevillard
    B Malfoy
    Oncogene, 2007, 26 : 6106 - 6112
  • [6] RB1 and TP53 pathways in radiation-induced sarcomas
    Gonin-Laurent, N.
    Hadj-Hamou, N. S.
    Vogt, N.
    Houdayer, C.
    Gauthiers-Villars, M.
    Dehainault, C.
    Sastre-Garau, X.
    Chevillard, S.
    Malfoy, B.
    ONCOGENE, 2007, 26 (41) : 6106 - 6112
  • [7] Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations.
    Chen, Monica F.
    Rakhade, Swanand
    Quintanal-Villalonga, Alvaro
    Lee, Jake
    Forsythe, Britney
    Moses, Khadeja A.
    Ahn, Linda Su Hyun
    Pupo, Amanda
    Falcon, Christina J.
    Rekhtman, Natasha
    Kris, Mark G.
    Rudin, Charles M.
    Chan, Joseph Minhow
    Yu, Helena Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Genetic Alterations of Both MEN1/ATRX and TP53/RB1 in Pancreatic Neuroendocrine Neoplasms
    Zhang, Ming-Yi
    He, Du
    Zhang, Shuang
    Liu, Ji-Yan
    PANCREAS, 2022, 51 (06) : e91 - e93
  • [9] Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
    Offin, Michael
    Chan, Joseph M.
    Tenet, Megan
    Rizvi, Hira A.
    Shen, Ronglai
    Riely, Gregory J.
    Rekhtman, Natasha
    Daneshbod, Yahya
    Quintanal-Villalonga, Alvaro
    Penson, Alexander
    Hellmann, Matthew D.
    Arcila, Maria E.
    Ladanyi, Marc
    Pe'er, Dana
    Kris, Mark G.
    Rudin, Charles M.
    Yu, Helena A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1784 - 1793
  • [10] Notch signaling and Tp53/RB1 pathway in pulmonary neuroendocrine tumorigenesis
    Ito, Takaaki
    Matsuo, Akira
    Hassan, Wael Abdo
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 (02) : 213 - 219
12345